28/8-1/9 Merab Kokaia speaks at The International Epilepsy Congress
Professor Merab Kokaia, one of CombiGene’s scientific founders, speaks at The International Epilepsy Congress
The 34th edition of The International Epilepsy Congress is held from 28 August to 1 September 2021. One of the speakers is Professor Merab Kokaia, one of CombiGene’s scientific founders. Merab will speak under the heading Pharmacoresistant epilepsy – neurobiological substrates for gene therapy.
The congress is organized by the International League Against Epilepsy (ILAE). The organization was founded in 1909 and is located in more than 120 countries.
Here is more information about the Congress:
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 firstname.lastname@example.org.
CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282